
    
      This study consists of 3 parts: the first and third part with standard doses and the second
      part with higher doses. All parts are randomized, placebo-controlled, observer-blind to
      evaluate the safety, tolerability and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV
      administered in different doses, sequences and schedules to healthy adult participants. The
      study consists of a screening period of up to 28 days, a vaccination period in which
      participants will be vaccinated at baseline (Day 1) followed by a boost on Day 15, 29, or 57,
      and third vaccine 1-year post-prime (3rd vaccination is optional for subjects in groups 1-8).
      The total duration of the study will be about 1 year for participants who wiil receive boost
      vaccine and about 3 months for participants who will receive placebo and 2 year for
      participants who will receive a 3rd dose. Safety will be monitored during the study.
    
  